<DOC>
	<DOCNO>NCT02210104</DOCNO>
	<brief_summary>The goal clinical research study learn safety give CD4+T cell ipilimumab cyclophosphamide . CD4+T cell type white blood cell . Researchers grow T cell laboratory , design find cancer cell may kill .</brief_summary>
	<brief_title>Adoptive Therapy Using Antigen-Specific CD4 T-Cells</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . The first 3 6 participant receive low dose ipilimumab . If intolerable side effect , second group 6 participant receive high dose ipilimumab . All study participant receive dose level cyclophosphamide CD4+T cell . Study Drug Administration : You receive cyclophosphamide vein 30-60 minute Day -2 ( 2 day receive CD4+T cell ) . If doctor think need , give standard drug help decrease risk side effect . You may ask study staff information drug give risk . On Day 0 , receive CD4+T cell vein 30-60 minute . You stay hospital overnight dose . On Days 1 , 22 , 43 , 64 , receive ipilimumab vein 90 minute . Study Visits : Within 2-4 week receive CD4+T cell : - You physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . - You compute tomography ( CT ) scan x-rays check status disease . On Day -2 : - You physical exam . - Blood ( 1 tablespoon ) drawn routine test . This routine blood draw include pregnancy test become pregnant . On Day 1 : - You physical exam . - Blood ( 1 tablespoon ) drawn routine test . On Days 0 , 7 , 14 , 22 , 28 , 35 , 43 , 49 , 56 : - You physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . On Day 3 , blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . Between Day 35 42 Day 77 84 , CT scan x-ray check status disease . The study test may repeat may additional test perform anytime doctor think need . Some study test may do local clinic return MD Anderson . The study staff discus . Length Study Drug Dosing : Your last study drug dose Day 64 . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up . End-of-Study-Drug-Dosing Visit : On Day 64 : - You physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . Follow-Up : On Days 70 , 77 , 84 , 105 , 126 , 147 , 168 : - You physical exam . - Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . Every 3 month Day 84 , unless disease get bad start another cancer therapy , CT scan x-ray check status disease . Every 3 month 5 year , study staff call ask doctor . If call , call last 10-15 minute . If doctor think need confirm status disease , blood ( 1½ tablespoon ) draw every 3 month 1 year . If doctor think need , return clinic every 4-6 week start Day 168 often doctor think need . These visit stop T-cells disappear disease get bad . Blood ( 5½ tablespoon ) draw routine test , immune system test , test long T-cells survive body . This investigational study . CD4+T cell FDA approve commercially available . They currently use research purpose . Cyclophosphamide FDA approve commercially available way use study . Ipilimumab FDA approve commercially available treatment melanoma , sarcoma . The study doctor explain study drug design work . Up 12 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histopathologic documentation melanoma , synovial sarcoma mixed round cell liposarcoma concurrent diagnosis metastatic disease . 2 . Tumor expression NYESO1 ( 2+ stain &gt; 25 % ) IHC . 3 . Male female subject ≥18 year age . 4 . Expression HLADPB1*0401 5 . Eastern Cooperative Oncology Group ( ECOG ) / Zubrod performance status '01 ' . 6 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study manner risk pregnancy minimize . Suggested precaution use minimize risk pregnancy least 1 month start therapy , woman study 3 month T cell infusion , least 8 week study drug stop . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal 7 . Men must willing able use acceptable method birth control , least 3 month completion study , sexual partner WOCBP . 8 . Willing able give inform consent . 9 . Adequate venous access consider peripherally inserted central venous catheter ( PICC ) central line 10 . Bidimensionally measurable disease palpation clinical exam , radiographic imaging ( Xray CT scan ) 11 . At least 4 week must elapse since last chemotherapy , immunotherapy , radiotherapy , major surgery . 12 . At least 6 week must elapse since last nitrosoureas , mitomycin C liposomal doxorubicin 13 . Toxicity related prior therapy must either return &lt; equal grade 1 , baseline , deem irreversible 1 . Patients active infection oral temperature &gt; 38.2 C within 71 hour Leukapheresis . The procedure may defer . 2 . Patients Hct &lt; 30 % , white blood count ( WBC ) &lt; 2500/uL platelet &lt; 50,000 immediately prior Leukapheresis . The procedure may defer . 3 . Any malignancy patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix . 4 . Complete blood count ( CBC ) Chemistry profile prior cyclophosphamide T cell infusion : WBC &lt; 2000/uL Hct &lt; 24 % Hb &lt; 8 g/dL absolute neutrophil count ( ANC ) &lt; 1000 Platelets &lt; 50,000 Creatinine &gt; 3.0 x ULN AST/ALT &gt; 2.5 x ULN Bilirubin &gt; 3 x ULN 5 . Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception . Women childbearing potential positive pregnancy test within 3 day prior entry . 6 . Clinically significant pulmonary dysfunction , determine medical history physical exam . Patients identify undergo pulmonary function test FEV1 &lt; 2.0 L DLco ( corr Hgb ) &lt; 75 % exclude . 7 . Significant cardiovascular abnormality define one following : Congestive heart failure , Clinically significant hypotension , Symptoms coronary artery disease , Presence cardiac arrhythmia EKG require drug therapy , Ejection fraction &lt; 50 % ( echocardiogram MUGA ) . 8 . Active untreated central nervous system ( CNS ) metastasis ( include metastasis identify screen MRI contrast CT ) . 9 . Autoimmune disease : Patients history Inflammatory Bowel Disease exclude study , patient history autoimmune disease ( e.g . Systemic Lupus Erythematosus , vasculitis , infiltrate lung disease ) whose possible progression treatment would consider Investigator unacceptable . 10 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation adverse event , condition associate frequent diarrhea . 11 . Positive screening test HIV , Hep B , Hep C. If positive result indicative true active chronic infection , patient treat . 12 . Steroids permit 3 day prior T cell infusion concurrently therapy . 13 . Any nononcology vaccine therapy use prevention infectious disease within 1 month ipilimumab dose . 14 . No prisoner child enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Mixed round cell liposarcoma</keyword>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>CD4+T Cells</keyword>
</DOC>